Interestingly, p.V600E accounted for about half BRAF mutations in NSCLC in earlier studies [42–46], and recent studies employing NGS technology exhibited that non-p.V600E mutations is the majority (70.0–80.0%) of BRAF mutations in NSCLC [32, 41, 47]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.